MP Advisors

An independent research company created in 1996, MP Advisors explores investment opportunities in the healthcare industry. The company keeps an eye on the industry as well as the main factors it is being influenced by. It also provides clients with a keen insight on major risks and rewards of investing in the pharmaceutical sector the world over, and particularly in Europe, the United States, Japan, Russia and India.

MP Advisors has a team of highly experienced and qualified researchers, analysts and financial consultants. The company’s employees gather, process and analyze information to then deliver it to the clients in the most understandable way. MP Advisors’ offerings grant access to fundamental assessments of various industries, allowing its clients to evaluate the emerging opportunities and gain maximum benefits.

The firm traces the historical and current performance of over 200 biotech and pharma companies worldwide; and publishes timely reports containing key opinion leaders assessments, snapshots of Japan and Indian generic drug and Para IV opportunities, therapy class reviews on several classes (e.g., hepatitis C, oncology, oral anticoagulants, obesity, etc.), among others. MP Advisors offers profound analyses of both long- and short-term investment opportunities.

Research Reports By MP Advisors

Found 445 publications
Enanta- It is just the beginning of good news US$ 90.00 Nov, 2013 2 pages
Therapy Class Overview: Rituximab biosimilar US$ 2,000.00 Oct, 2013 45 pages
1 2 3 4 5 ... 9
Skip to top

News & Press-Releases by MP Advisors